Literature DB >> 24969954

[Reproductive options for people living with HIV: 2013 guidelines from the French expert working group].

L Mandelbrot1, A Berrebi2, C Rouzioux3, M Partisani4, P Faucher5, R Tubiana6, S Matheron7, L Bujan8, P Morlat9.   

Abstract

The desire for children is a legitimate aspiration that should be part of multidisciplinary care for all men, women or couples living with HIV. The use of effective antiretroviral therapy has revolutionized the prevention of sexual, as well as mother-to-child HIV transmission. When the HIV plasma viral load is undetectable on long-term antiretroviral therapy, the risk of mother-to-child transmission is <1% and the risk of heterosexual HIV transmission without condom use in a stable relationship is very low (estimated at less than 1/10,000) in the absence of inflammation of the genital tract. In a man with a long-term undetectable viral load, viral shedding in semen is uncommon, but may occur persistently or intermittently. The same appears true of viral shedding in the vaginal tract of women. Reproductive options are: natural conception, self-insemination when the woman is HIV-infected, assisted reproduction. Natural conception is now considered to be an acceptable option when the conditions are met, after exploring four aspects: (1) virological (viral load undetectable sustained for at least 6 months on therapy), (2) genital (absence of genital infections or lesions), (3) fertility (after appropriate evaluation) and (4) detecting the ovulation period to limit intercourse without condoms. Assisted reproduction has two objectives in the context of HIV, to allow the couple to conceive without abandoning condom use and/or to treat infertility.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  AMP; Assisted reproduction techniques; HIV; Heterosexual transmission; Procréation; Reproduction; Risque viral; Semen; Sperme; Transmission hétérosexuelle; VIH; Viral risk

Mesh:

Substances:

Year:  2014        PMID: 24969954     DOI: 10.1016/j.gyobfe.2014.05.019

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  7 in total

1.  Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014.

Authors:  Charles Cazanave; Sandrine Reigadas; Cyril Mazubert; Pantxika Bellecave; Mojgan Hessamfar; Fabien Le Marec; Estibaliz Lazaro; Gilles Peytavin; Mathias Bruyand; Hervé Fleury; François Dabis; Didier Neau
Journal:  Open Forum Infect Dis       Date:  2015-03-12       Impact factor: 3.835

2.  Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.

Authors:  Nicolas Noel; Nathalie Lerolle; Camille Lécuroux; Cécile Goujard; Alain Venet; Asier Saez-Cirion; Veronique Avettand-Fenoël; Laurence Meyer; Faroudy Boufassa; Olivier Lambotte
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

3.  Influence of the First Consultation on Adherence to Antiretroviral Therapy for HIV-infected Patients.

Authors:  Marion Peyre; Aurélie Gauchet; Matthieu Roustit; Pascale Leclercq; Olivier Epaulard
Journal:  Open AIDS J       Date:  2016-09-07

4.  Prevalence of anal symptoms in general practice: a prospective study.

Authors:  Géraldine Tournu; Laurent Abramowitz; Camille Couffignal; Frédéric Juguet; Agnès Sénéjoux; Stéphane Berger; Anne-Laure Wiart; Marc Bernard; Françoise Provost; Hélène Pillant-Le Moult; Dominique Bouchard; Jean-Pierre Aubert
Journal:  BMC Fam Pract       Date:  2017-08-03       Impact factor: 2.497

5.  Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study.

Authors:  Jorge Del Romero; María Begoña Baza; Isabel Río; Adrián Jerónimo; Mar Vera; Victoria Hernando; Carmen Rodríguez; Jesús Castilla
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

6.  Prevalence and incidence of kidney diseases leading to hospital admission in people living with HIV in France: an observational nationwide study.

Authors:  Magali Louis; Jonathan Cottenet; Arnaud Salmon-Rousseau; Mathieu Blot; Pierre-Henri Bonnot; Jean-Michel Rebibou; Pascal Chavanet; Christiane Mousson; Catherine Quantin; Lionel Piroth
Journal:  BMJ Open       Date:  2019-05-05       Impact factor: 2.692

7.  "Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.

Authors:  Pierre Gantner; Babacar Sylla; Laurence Morand-Joubert; Pierre Frange; Karine Lacombe; Marie-Aude Khuong; Claudine Duvivier; Odile Launay; Marina Karmochkine; Cédric Arvieux; Amélie Ménard; Lionel Piroth; Ana Canestri; Dominique Trias; Gilles Peytavin; Roland Landman; Jade Ghosn
Journal:  PLoS One       Date:  2019-04-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.